Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFICACY AND TOLERABILITY OF MILNACIPRAN - AN OVERVIEW
Autore:
MONTGOMERY SA; PROST JF; SOLLES A; BRILEY M;
Indirizzi:
ST MARYS HOSP,SCH MED LONDON W2 1NY ENGLAND INST RECH PIERRE FABRE F-92654 BOULOGNE FRANCE CTR RECH PIERRE FABRE F-81100 CASTRES FRANCE
Titolo Testata:
International clinical psychopharmacology
, volume: 11, anno: 1996, supplemento:, 4
pagine: 47 - 51
SICI:
0268-1315(1996)11:<47:EATOM->2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; DEPRESSION; DRUG; ANTIDEPRESSANT; MIDALCIPRAN; VOLUNTEERS; F-2207;
Keywords:
MILNACIPRAN; TRICYCLIC; ANTIDEPRESSANTS; SELECTIVE SEROTONIN REUPTAKE INHIBITORS; ANTIDEPRESSANT EFFICACY; ADVERSE EVENTS; THERAPEUTIC;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
S.A. Montgomery et al., "EFFICACY AND TOLERABILITY OF MILNACIPRAN - AN OVERVIEW", International clinical psychopharmacology, 11, 1996, pp. 47-51

Abstract

The relative benefits and risks of milnacipran, a novel antidepressant which selectively inhibits the reuptake of serotonin and noradrenaline, have been evaluated in comparative trials against tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs). Atotal of 2462 patients with major depressive disorders have been investigated. At the optimal dose (50 mg twice a day), the efficacy of milnacipran was equivalent to that of the TCAs, with response rates of approximately 65% in both cases. Milnacipran was consistently effective against all of the principal elements of depression (anxiety, cognitive function, sleep and psychomotor retardation), and did not produce sedation or the emergence of suicidal thoughts. The Clinical Global Impression (CGI-3) score, a measure of the overall therapeutic impact of atreatment, was significantly higher with milnacipran than with TCAs (1.98 versus 1.84, p < 0.05). TCAs were associated with a higher frequency of adverse events than milnacipran, particularly with respect to anticholinergic-like effects; dysuria was the only adverse event occurring twice as frequently with milnacipran than with TCAs. Compared withTCAs, milnacipran was also associated with a lower incidence of cardiovascular adverse events. No haematological abnormalities occurred during treatment with milnacipran, and the incidence of abnormal liver function tests tended to be lower with milnacipran than with TCAs. In comparisons with SSRIs, milnacipran produced significantly higher response rates. The CGI-3 scores were significantly higher in milnacipran-treated patients (2.64 versus 2.32, p < 0.05). The adverse event profiles of the two treatments were similar, as was the incidence of abnormalliver function tests. These studies suggest that milnacipran offers clinical advantages over TCAs in terms of tolerability, and over SSRIs in terms of efficacy. In particular, the lack of cardiovascular adverse events appears to offer advantages in cases of deliberate overdose. To date, 15 such overdoses have occurred; none was fatal and each had a favourable outcome. The reproducible pharmacokinetic characteristicsof milnacipran present further advantages over both groups of agents,due to lack of drug accumulation and a low risk of drug interactions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 00:20:24